Saturday, 20 April 2024
Dova Pharmaceuticals Inc.
18:15 | 11/1/18
Frisco Fastball
More notable recent Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) news were published by: Marketwatch.com which released: “Dova Pharmaceuticals Inc.” on June 08, 2017, also Benzinga.com with their article: “43% Upside Seen For Dova Pharma Following ...
more»
08:07 | 10/1/18
Post Analyst
Netlist, Inc. (NLST) has made its way to a 12-month decline of -66.47%. Turning to Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), its shares were trading at $29.19 a gain of $0.64, on the trading floor.
more»
08:30 | 5/1/18
Simply Wall St
In this article, I will take a quick look at Dova Pharmaceuticals Inc's (NASDAQ:DOVA) recent ownership structure - an unconventional investing subject, but an important one.
more»
10:00 | 4/1/18
GlobeNewswire
DURHAM, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Following two separate meetings with the U.S. Food and Drug Administration (FDA), Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) plans to submit a Supplemental New Drug Application (sNDA) in the second half of ...
more»
01:00 | 11/12/17
The Ledger Gazette
Dova Pharmaceuticals logo Perceptive Advisors LLC grew its stake in shares of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
more»
10:22 | 5/12/17
GlobeNewswire
DURHAM, N.C., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that the Company will present four abstracts, three of which will be oral presentations, with data from Phase 3 clinical trials of avatrombopag in ...
more»
21:48 | 29/11/17
WRAL Tech Wire
Durham, N.C. - ?Dova Pharmaceuticals Inc. announced that its first drug has been submitted with priority review for Food and Drug Administration approval, according to a filing Tuesday with the Securities and Exchange Commission.
more»
01:33 | 29/11/17
StreetInsider.com
Jefferies analyst, Eun Yang, reiterated her Buy rating on shares of Dova Pharmaceuticals Inc (NASDAQ: DOVA) and raised her price target to $33 from $30 after the company announced that it received FDA priority review for Avatrombopag, with PDUFA date ...
more»
10:00 | 28/11/17
GlobeNewswire
DURHAM, N.C., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the New Drug Application (NDA) for avatrombopag has been accepted for filing and has been granted Priority Review by the United ...
more»
02:30 | 22/11/17
GlobeNewswire
DURHAM, N.C., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Evercore ISI Biopharma Catalyst/Deep Dive ...
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |